Prolor Biotech
Subscribe to Newsletter
Home
About PROLOR Biotech
Board of Directors
Phillip Frost, M.D. (Chairman)
Marian Gorecki, Ph.D.
Abraham Havron, Ph.D.
Jane Hsiao, Ph.D.
Steve Rubin, J.D.
Fuad Fares, D.Sc.
Shai Novik
Management Team
Abraham Havron, Ph.D. - Chief Executive Officer
Eyal Fima, Ph.D. - Chief Operating Officer
Fuad Fares, D.Sc. - Chief Scientific Officer
Shai Novik - President
Products
hGH-CTP: Human Growth Hormone
FVII-CTP: Factor VIIa
GLP-1 / Glucagon dual receptor agonist
Technologies
Attempts to Extend the Life
CTP Competitive Advantages
CTP Scientific Papers
About RevPEG
Intellectual Property
Facilities & Production
Clinical Trials
hGH-CTP Phase I Data
hGH-CTP Phase II Data
Merck's FSH-CTP European Marketing Approval
Merck's Phase III and II FSH-CTP trial
Partnering
The Therapeutic Proteins Industry
The Challenges of Developing New Drugs
The Advantage of Developing Biobetter Versions of Existing Drugs
Investor Relations
News
News
SEC Filings
Company Information
Contact
Financials
Quote
Charts
Historical Prices
Financials
Contact Us
Navigation
Subscribe
Search
Management Team
News
4/24/2013 2:00:00 AM
OPKO Health To Acquire PROLOR Biotech
4/8/2013 7:30:00 AM
PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX
Learn More
About
PROLOR biotech
Read
Technology
CTP Competitive Advantages
Read
Clinical Experience
The Story of FSH - CTP
Read
Abraham Havron, Ph.D. - Chief Executive Officer
Eyal Fima, Ph.D. - Chief Operating Officer
Fuad Fares, D.Sc. - Chief Scientific Officer
Shai Novik - President